Alphatec Holdings (ATEC) risk factors, FY2024 10-K

Alphatec Holdings's FY2024 10-K, filed Feb 26, 2025, lists 42 risk factors in 4 groups. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Risk factors listed
424 groups
Section length
10k wordsItem 1A

Alphatec Holdings's biggest risks in the FY2024 10-K

  • Alphatec Holdings faces intense competition in the spine surgery market from large established device makers.
  • The company relies heavily on systems featuring polyaxial pedicle screws and a single supplier, Invibio, for PEEK raw materials.
  • Financial performance is constrained by a history of net losses and a $1.3 billion accumulated deficit.

The risks most specific to Alphatec Holdings

  • Risks Related to Our Business and Industry

    We operate in a highly competitive market segment, face competition from large, well-established medical device companies with significant resources, and may not be able to compete effectively

    We compete with large, well-capitalized medical device companies including Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet, and Globus Medical.

  • Risks Related to Our Business and Industry

    A significant percentage of our revenues are derived from sales of our systems that include polyaxial pedicle screws

    Sales of systems that include polyaxial pedicle screws accounted for approximately 40% and 41% of our net sales for 2024 and 2023, respectively.

  • Risks Related to Our Business and Industry

    We depend on third-party suppliers, and in one case a single supplier, for key raw materials and the loss of any of these third-party suppliers, or their inability to supply us with adequate raw materials, could harm our business

    We depend on a single source vendor, Invibio, to provide PEEK, a biocompatible plastic used in some of our spacers.

  • Risks Related to Our Financial Results, Credit and Certain Financial Obligations and Need for Financing

    We may need to raise additional funds in the future and such funds may not be available on acceptable terms, if at all

    Our principal sources of liquidity at December 31, 2024 included cash and cash equivalents of $138.8 million and a revolving credit facility with MidCap Financial Trust.

  • Risks Related to Our Financial Results, Credit and Certain Financial Obligations and Need for Financing

    Covenants in our loan documents and indenture may restrict our business and operations and if we do not effectively manage our covenants, our financial condition and results of operations could be adversely affected

    Our revolving credit facility, the Braidwell Term Loan, and our 0.75% Convertible Senior Notes due 2026 contain restrictive financial and operating covenants.

  • Risks Related to Our Financial Results, Credit and Certain Financial Obligations and Need for Financing

    We have a history of net losses, we expect to continue to incur net losses in the near future, and we may not achieve or maintain profitability

    We have incurred significant net losses since inception and had an accumulated deficit of $1.3 billion as of December 31, 2024.

All 42 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business and Industry

  1. 01Our business plan relies on certain assumptions pertaining to the market for our products that, if incorrect, may adversely affect our growth and profitability
  2. 02We operate in a highly competitive market segment, face competition from large, well-established medical device companies with significant resources, and may not be able to compete effectively
  3. 03greater experience in obtaining and maintaining FDA and other regulatory clearances or approvals for products and product enhancements
  4. 04A significant percentage of our revenues are derived from sales of our systems that include polyaxial pedicle screws
  5. 05Our reliance on sales agents could affect our ability to market our products efficiently and profitably
  6. 06To be commercially successful, we must convince the spine surgeon community that our products are an attractive alternative to competitive products
  7. 07We rely on a limited number of third parties to manufacture and supply our products. Any problems experienced by these manufacturers could result in a delay or interruption in the supply of our products until such manufacturer cures the problem or until we locate and qualify an alternative source of supply
  8. 08We depend on third-party suppliers, and in one case a single supplier, for key raw materials and the loss of any of these third-party suppliers, or their inability to supply us with adequate raw materials, could harm our business
  9. 09If we or our suppliers fail to comply with applicable regulations, the manufacture of our products could be delayed
  10. 10Demand for our products, and prices at which customers and patients are willing to pay for our products depend upon the ability of our customers to obtain adequate third-party coverage and reimbursement product purchases
  11. 11Operation of our business internationally is subject to our continued compliance with the laws and regulations of each country in which we operate, as well as the business and legal customs in those jurisdictions and geographies
  12. 12Consolidation in the healthcare industry could lead to price concessions or exclusion of some suppliers from some markets, which could have an adverse effect on our business, financial condition or results of operations
  13. 13We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse, health information privacy and security, and disclosure laws, and could face substantial penalties if we are unable to fully comply with such laws
  14. 14a variety of state-imposed privacy and data security laws which require the protection of personal information beyond health information and which require reporting to state officials in the event of breach or violation and which impose both civil and criminal penalties
  15. 15If we fail to timely obtain governmental clearances or approvals for our future products or modifications to our products, our ability to commercially distribute and market our products could suffer
  16. 16If we choose to acquire new and complementary businesses, products or technologies, we may be unable to complete these acquisitions or successfully integrate them in a cost-effective and non-disruptive manner
  17. 17We are dependent on our senior management team, sales and marketing team, engineering team and key surgeon advisors, and the loss of any of them could harm our business
  18. 18Nearly all of our operations are currently conducted in locations that may be at risk of damage from fire, earthquakes or other natural disasters
  19. 19Public health crises, political crises, and other catastrophic events or other events outside of our control may impact our business
  20. 20Alphatec Holdings is a holding company with no operations, and unless it receives dividends or other payments from its subsidiaries, it will be unable to fulfill its cash obligations
  21. 21If we fail to properly manage our anticipated growth, our business could suffer
  22. 22The use of artificial intelligence ("AI") technology by our employees or business partners could result in misuse or loss of proprietary information, violation of laws and regulations, or damage to our reputation and credibility

Risks Related to Our Financial Results, Credit and Certain Financial Obligations and Need for Financing

  1. 23We may need to raise additional funds in the future and such funds may not be available on acceptable terms, if at all
  2. 24the costs associated with our employee retention programs and related benefits
  3. 25Covenants in our loan documents and indenture may restrict our business and operations and if we do not effectively manage our covenants, our financial condition and results of operations could be adversely affected
  4. 26We have a history of net losses, we expect to continue to incur net losses in the near future, and we may not achieve or maintain profitability
  5. 27A significant economic downturn or volatility in the economy in any market in which we operate could have a material adverse impact on our business, financial condition, results of operations, or cash flows
  6. 28Our quarterly financial results could fluctuate significantly
  7. 29In addition, until we have a larger base of spine surgeons using our products, occasional fluctuations in the use of our products by individual surgeons or small groups of surgeons will have a proportionately larger impact on our revenues than for companies with a larger customer base

Risks Related to Our Intellectual Property, Regulatory Penalties and Litigation

  1. 30If our patents and other intellectual property rights do not adequately protect our products, we may lose market share to our competitors and be unable to operate our business profitably
  2. 31The medical device industry is characterized by patent and other intellectual property litigation and we could become subject to litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, and/or prevent us from marketing our existing or future products
  3. 32also be existing patents that one or more components of our products may be inadvertently infringing, of which we are unaware. As the number of participants in the market for spine disorder devices and treatments increases, the possibility of patent infringement claims against us also increases
  4. 33If we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage
  5. 34Because biologics products entail a potential risk of communicable disease to human recipients, we may be the subject of product liability claims regarding our biologics products
  6. 35Any claims relating to our improper handling, storage or disposal of biological, hazardous and radioactive materials could be time consuming and costly

Risks Related to Our Common Stock

  1. 36Our stock price may fluctuate significantly, particularly if holders of substantial amounts of our stock attempt to sell, and holders may have difficulty selling their shares based on trading volumes of our stock
  2. 37We may become involved in securities class action litigation that could divert management’s attention and harm our business
  3. 38Securities analysts may not provide coverage of our common stock or may issue negative reports, which may have a negative impact on the market price of our common stock
  4. 39Because of their significant stock ownership, our executive officers, directors and principal stockholders will be able to exert control over us and our significant corporate decisions
  5. 40limit who may call stockholder meetings
  6. 41Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
  7. 42We could be subject to changes in our tax rates, new tax legislation or additional tax liabilities

Other Alphatec Holdings 10-Ks

  • FY2025 10-K risk factors
    44 risks3 new1 dropped4 reworded

    The company added specific risks regarding FDA backlogs, import tariffs, and tax compliance. Patent infringement and tax risks were reworded.

    Filed Feb 24, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.